IKT - NASDAQ
Inhibikase Therapeutics, Inc.
$1.67
-1.5%Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
At a Glance
Live SnapshotInhibikase Therapeutics, Inc. Management Team
Mr. Mark T. Iwicki
Chief Executive Officer & Director
Mr. David John McIntyre B.Econs(Acc), BEC, C.P.A., L.L.B., M.B.A.
Chief Financial Officer
Mr. Jeffrey J. Kagy
Chief Human Resources Officer
Dr. John Adams Ph.D.
Chief Scientific Officer
Mr. Chadwick J. Orevillo MPH
Executive Vice President & Head of Development Operations
Dr. Christopher H. Cabell FACC, M.D.
President, Head of Research & Development and Chief Medical Officer
Inhibikase Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $4.27M worth of IKT shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
2.1M
3.00M
0
0.00
+3.0M
+$3.00M
9-12 Months
649.1K
1.27M
0
0.00
+1.3M
+$1.27M
Top Buyers
Sands Capital Life Sciences Pulse Fund Ii, L.P.
10 Percent Owner
$3.00M
Kush Arvind
Director
$211K
Berman Dennis N
Director
$211K
Bellini Roberto
Director
$211K
Munshi Amit
Director
$211K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $4.27M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
IKT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 26, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | May 12, 2025 | June 27, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | November 18, 2024 | January 03, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | June 20, 2024 | August 05, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 07, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 05, 2023 | June 23, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | May 02, 2022 | June 24, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 25, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.